A Phase 3 interventional study of Nurse-led preemptive symptom management and Concentional care in Head and Neck Cancer, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by West China Hospital · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Head and Neck Neoplasms by West China Hospital — 10 open to participants now, 11 under way, 2 of them phase 3. Head and Neck Neoplasms · West China Hospital.
Among the 19 studies in Head and Neck Neoplasms by West China Hospital, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 7 that started in 2026, is the only one in phase 3, reaches primary completion later than 6 of the 10 other live ones, and was the 13th registered.
2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.
Browse Head and Neck Neoplasms studies →10 of the 19 studies in Head and Neck Neoplasms by West China Hospital are open now, in 1 country. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 18–80
West China Hospital · Sites in China
Ages 18–80
West China Hospital · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18–65
West China Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 2
First in 2020; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is above the median of 46 across 2,036 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 40 across the 17 interventional studies, 12 across the 2 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.
7 of the studies in Head and Neck Neoplasms by West China Hospital that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07353671Phase 3West China HospitalTopical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis | 2026-12-31 |
| NCT07467083Phase 3West China HospitalDevelopment and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy | 2027-03-01 |
| NCT07635277West China HospitalAkkermansia Muciniphila (AKK) for Radiation-Induced Skin Injury | 2026-11-30 |
| NCT07704372West China HospitalSuperoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer | 2027-01-31 |
| NCT07583914West China HospitalSafety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 19 studies in Head and Neck Neoplasms by West China Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate whether a nurse-led preemptive symptom management protocol can reduce the radiation therapy interruption rate in patients with head and neck cancer compared to conventional care models.
The aim of this study is to investigate whether a nurse-led preemptive symptom management protocol can reduce the radiation therapy interruption rate in patients with head and neck cancer compared to conventional care models. The secondary objective is to evaluate whether the nurse-led preemptive symptom management protocol improves symptoms, quality of life, and psychological well-being in head and neck cancer patients undergoing radiation therapy compared to conventional care models.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the intervention group will receive a structured nurse-led preemptive symptom management protocol. This protocol, centered around trained oncology specialist nurses, involves systematic visits conducted before, during, and after radiotherapy. The intervention encompasses four key components: symptom monitoring and management guided by a standardized manual, emotional and psychological support integrating family involvement and traditional cultural values, family-unit-based education and skills training, and care coordination ensuring multidisciplinary communication. The core of the intervention is the nurse's sustained engagement to proactively prevent and manage symptoms while reinforcing the family's role within the support system.
Behavioral: Nurse-led preemptive symptom management
Patients in the control group will receive conventional care, which encompasses standardized nursing procedures, routine health education (including information related to radiotherapy) and so on.
Behavioral: Concentional care
The intervention encompasses four key components: symptom monitoring and management guided by a standardized manual, emotional and psychological support integrating family involvement and traditional cultural values, family-unit-based education and skills training, and care coordination ensuring multidisciplinary communication.
Conventional care encompasses basic nursing care and routine health education, including instruction related to radiotherapy.
Radiotherapy interruption rate
The number of patients who missed five or more consecutive radiations and the reasons for this are recorded during radiotherapy.
Time frame: The time period is the period from the start of radiotherapy to the completion of radiotherapy.The evaluation period is approximately 6 weeks and 6.5 weeks.
Rehospitalization rate
Rehospitalization was defined as any unplanned hospital admission within 3 months after completing radiotherapy for reasons unrelated to antitumor treatment.
Time frame: The time frame spans from the commencement of radiotherapy to three months post-radiotherapy, with an approximate total evaluation period of five months.
Quality of life as sssessed by the EORTC QLQ-C30 Questionnaires
European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30). This is a 30-item questionnaire assessing quality of life in cancer patients through functional scales, symptom scales, and a global health status scale. Scores are transformed to a 0-100 scale. For functional scales and global health status, higher scores indicate better quality of life; for symptom scales, higher scores indicate worse symptoms.
Time frame: 1 week before radiotherapy ; at the middle of radiotherapy (usually 3 weeks after the start of radiotherapy) ; at the end of radiotherapy(the last radiation dose received, usually 6 or 6.5 weeks) ; and 1, 2, 3 months after the end of radiotherapy.
Quality of life as sssessed by the EORTC QLQ-H&N35 Questionnaires
European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Head and Neck Cancer Module (EORTC QLQ-H\&N35). This is a 35-item module specifically designed for patients with head and neck cancer, assessing symptoms and side effects related to the disease and treatment. All items are scored on a 0-100 scale, where higher scores represent worse symptoms or more problems.
Time frame: 1 week before radiotherapy ; at the middle of radiotherapy (usually 3 weeks after the start of radiotherapy) ; at the end of radiotherapy(the last radiation dose received, usually 6 or 6.5 weeks) ; and 1, 2, 3 months after the end of radiotherapy.
Symptom burden
The symptom burden of the patients was evaluated using the M.D. Anderson Symptom Inventory (MDASI). This is a brief, multi-symptom assessment tool comprising 13 core symptom items and 6 interference items. Each item is rated on an 11-point numeric scale ranging from 0 to 10. For all items, higher scores indicate greater symptom severity or greater interference with daily functioning.
Time frame: Weekly during radiotherapy and 1, 2, and 3 months post-radiotherapy.The evaluation period is approximately 5 months.
Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
This 7-item subscale assesses anxiety symptoms. Each item is rated on a 4-point scale (0 to 3), and scores are summed to yield a total score ranging from 0 to 21. Higher scores indicate greater anxiety severity (worse outcome).
Time frame: Weekly during radiotherapy and 1, 2, and 3 months post-radiotherapy.The evaluation period is approximately 5 months.
Hospital Anxiety and Depression Scale (HADS) - Depression Subscale
This 7-item subscale assesses depressive symptoms. Each item is rated on a 4-point scale (0 to 3), and scores are summed to yield a total score ranging from 0 to 21. Higher scores indicate greater depression severity (worse outcome).
Time frame: Weekly during radiotherapy and 1, 2, and 3 months post-radiotherapy.The evaluation period is approximately 5 months.
Adverse events
Adverse events were assessed and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0. Each adverse event is assigned a grade from 1 to 5, where Grade 1 indicates mild symptoms, Grade 2 moderate, Grade 3 severe or medically significant, Grade 4 life-threatening consequences, and Grade 5 death related to the adverse event. Higher grades represent greater severity (worse outcome).
Time frame: From the first day of radiotherapy to the day of the last radiation dose received, usually 6 or 6.5 weeks.
Tumor response
Tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Based on this criteria, tumor response is categorized into one of four ordinal categories: Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD). CR and PR represent objective tumor response (better outcome), while PD represents disease progression (worse outcome).
Time frame: From the initiation of radiotherapy until three months after its completion.The evaluation period is approximately 5 months.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.
Of 48 non-industry phase 3 interventional studies under Head and Neck Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 108. This study's planned 11 months is below that.
Counting every sponsor, half of 66 studies reached it within 61 months; a quarter within 34 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.